However, several clinical trials have shown that the accuracy of these genes in predicting the response to PARPis is similar to that of BRCA1/2 in patients with recurrent ovarian cancer and even lessened when olaparib is combined with bevacizumab in newly diagnosed patients [41, 42]. The gene discussed is BRCA1; the disease is ovarian cancer.